Arquer Diagnostics News Today

Olaparib plus abiraterone acetate delayed disease progression and improved outcomes in patients with BRCA-, ATM- and CDK12-mutated mCRPC.

Cretostimogene grenadenorepvec in combination with pembrolizumab produced high complete response rates with a tolerable safety profile in patients with Bacillus Calmette-Guérin–unresponsive non–muscle invasive bladder cancer.

Arquer Diagnostics ADXBLADDER Becomes First Bladder Cancer Urine Test To Undergo Rigorous Clinical Trials In USA First patients recruited for bladder cancer recurrence monitoring study News provided by Share this article SUNDERLAND, England, July 27, 2021 /PRNewswire/ -- ADXBLADDER has become the first new generation urinary biomarker test for bladder cancer to undergo rigorous clinical trials in the USA in decades. The innovative and highly accurate test, developed by UK company Arquer Diagno...

Survey finds misdiagnosis and delays putting women's lives at risk SUNDERLAND, England, May 6, 2021 /PRNewswire/ -- Women with bladder cancer symptoms feel ignored by their doctor, face